In round 2, 84% agreed that ALF should be the severe liver disease endpoint while acute hepatitis should be the moderately severe liver disease endpoint, and most (84%) participants felt that ALT should be evaluated for all trial participants with an acute febrile illness. The gene discussed is GPT; the disease is Acute hepatitis.